Literature DB >> 7858927

Viral infections in severely immunocompromised cancer patients.

S M Devine1, J R Wingard.   

Abstract

Immunocompromised cancer patients are susceptible to infection by many viral pathogens. The most serious morbidity results from active infection by members of the herpes virus family. Reactivation of latent virus occurs as a sequela of cytotoxic therapy and deficiency of cell-mediated immunity, especially cytotoxic responses, the major host protective defense. Herpes simplex virus and varicella zoster virus infections are problematic in patients with all types of cancer; cytomegalovirus infections cause life-threatening morbidity in bone marrow transplant patients. Several antiviral agents are highly active against these pathogens and different strategies of using them have resulted in reduced morbidity and mortality. Ultimately, the resolution of these infections is dependent on the control of the malignancy and the ability of the patient to mount an adequate immune response.

Entities:  

Mesh:

Year:  1994        PMID: 7858927     DOI: 10.1007/bf00344048

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  115 in total

1.  A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group.

Authors:  P Ljungman; B Lönnqvist; O Ringdén; P Skinhöj; G Gahrton
Journal:  Bone Marrow Transplant       Date:  1989-11       Impact factor: 5.483

2.  Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Two cases after HLA-mismatched bone marrow transplantation.

Authors:  S Blanche; F Le Deist; F Veber; G Lenoir; A M Fischer; J Brochier; C Boucheix; M Delaage; C Griscelli; A Fischer
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

3.  Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen.

Authors:  P D Swenson; M H Kaplan
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

4.  Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation.

Authors:  T J Perren; R L Powles; D Easton; K Stolle; P J Selby
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

5.  Risk factors for cytomegalovirus infection after human marrow transplantation.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

6.  Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients.

Authors:  J A Zaia; S J Forman; Y P Ting; E Vanderwal-Urbina; K G Blume
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

7.  Pretransplant herpesvirus serology and acute graft-versus-host disease.

Authors:  L Boström; O Ringdén; B Sundberg; A Linde; J Tollemar; B Nilsson
Journal:  Transplantation       Date:  1988-10       Impact factor: 4.939

8.  Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation.

Authors:  J C Wade; B Newton; N Flournoy; J D Meyers
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

9.  Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients.

Authors:  J W Gratama; E T Lennette; B Lönnqvist; M A Oosterveer; G Klein; O Ringdén; I Ernberg
Journal:  J Med Virol       Date:  1992-05       Impact factor: 2.327

10.  Acyclovir prophylaxis of herpes-simplex-virus infections.

Authors:  R Saral; W H Burns; O L Laskin; G W Santos; P S Lietman
Journal:  N Engl J Med       Date:  1981-07-09       Impact factor: 91.245

View more
  2 in total

1.  Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR.

Authors:  V N Loparev; T Argaw; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

2.  Assessment of oral cytological changes associated with exposure to chemotherapy and/or radiotherapy.

Authors:  Hussain G Ahmed; Dalia Ai Elemirri
Journal:  Cytojournal       Date:  2009-05-16       Impact factor: 2.091

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.